Clay Siegall serves as the President and the Chief Executive Officer (CEO) of the Seattle Genetics, Inc. He is also the chairman of the board of the company. He is the co-founder the company that is accredited for scientific innovations particularly in the treatment of cancer. His education background is the field of science where he pursued a B.S in Zoology at the University of Maryland and later obtained his Ph.D. in genetics from George Washington University.
Similarly, Dr. Clay has much experience in cancer research and development of treatment therapies. Besides, he is the author of at least 67 journal papers that are scientific and have several patents. His career began in 1988 as a fellow at the National Cancer Institute within the National Institutes of Health until 1991. In 1995, Dr. Clay received Pierce Award for his excellent work pertaining targeted toxins. He was also awarded in 2002 the Ernst and Young Entrepreneur of the Year in the category of healthcare.
Furthermore, he served as a senior research investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute between the year 1991 and 1995. He also served as the principal scientist in the same organizations until 1997 when he co-founded Seattle Genetics. He was the director of Alder, Biopharmaceuticals Inc., Washington Biotechnology, and Biomedical Association. Similarly, he served as the on the board of governors of the Fred Hutchinson Cancer Research business alliance.
Besides working in various scientific institutions, Dr. Clay is a member of the Cancer Treatment Research Foundation. He also serves on the editorial board of three scientific journals. He lays much emphasis on targeted therapies relating to cancer. Under his leadership, Seattle Genetics has developed an antibody-drug conjugates product that was approved by the FDA in 2011. The company collaborated with Takeda Pharmaceuticals to develop ADCETRIS drug used in cancer treatment.
Finally, Clay Siegall has portrayed strategic leadership enabling Seattle Genetics to partner with pharmaceuticals like Pfizer in ADC technology. He helped raise capital from the public and private to develop the company. In addition, Dr. Clay is driven by the need to help the patients, thus reduce the impact of cancer in the society.